Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 16Recurrence 3Neoplasms, Plasma Cell 2Renal Insufficiency 1Paraproteinemias 1Neoplasms by Histologic Type 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hypoxia 1High Grade Squamous Intra-epithelial Lesion (HSIL) 1Hematologic Diseases 1Disease Progression 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Dexamethasone 3isatuximab 2Lenalidomide 2pomalidomide 1daratumumab 1Ranitidine 1Diphenhydramine 1Cyclophosphamide 1Bortezomib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Blood Protein Disorders × pomalidomide × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡